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Over the recent years, Next Generation Sequencing (NGS) technologies targeting the microRNA transcrip-
tome revealed the existence of many different RNA fragments derived from small RNA species other than
microRNA. Although initially discarded as RNA turnover artifacts, accumulating evidence suggests that
RNA fragments derived from small nucleolar RNA (snoRNA) and transfer RNA (tRNA) are not just random
degradation products but rather stable entities, which may have functional activity in the normal and
malignant cell.
This review summarizes new ﬁndings describing the detection and alterations in expression of
snoRNA-derived (sdRNA) and tRNA-derived (tRF) RNAs. We focus on the possible interactions of sdRNAs
and tRFs with the canonical microRNA pathways in the cell and present current hypotheses on the func-
tion of these RNAs.
 2013 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Within less than a decade since the sequencing of the human
genome it became clear that over ninety percent of our genes en-
code for RNA transcripts that never get translated to protein. The
cellular pool of these so-called non-protein-coding RNAs (ncRNA)
[1] is highly complex in terms of its diversity and function. Differ-
ent structural and functional classes of ncRNA act as regulators of
key cellular processes, many of which are associated with cancer.
Within the diverse group of ncRNA, small non-coding RNA and
in particular microRNAs (miRNAs) have been the focus of much
attention over the recent years because of their function as post-
transcriptional modulators of gene expression during development
and disease. The ﬁrst small regulatory miRNA, lin-4, originally
called small temporal RNA, was discovered in Caenorhabditis ele-
gans in 1993 [2]. The development of next generation (deep)
sequencing (NGS) technologies advanced the discovery of over
1900 distinct mature miRNAs originating from more than 1520
miRNA gene loci in human only (miRBase, Release 18, http://
www.mirbase.org/, November 2011 and [3]). It is well established
now that miRNAs have essential regulatory roles in cell prolifera-
tion, differentiation, apoptosis, and metabolism; and that altera-
tions in miRNA function are involved in the pathogenesis of
cancer and many other human diseases [4,5].Alongside with miRNA, other types of small regulatory ncRNAs
like exogenous and endogenous small interfering RNAs (siRNAs
and endo-siRNAs) [6–8] and PiWi-interacting RNAs (piRNAs) [9]
are also involved in gene regulation and genome defense and share
components of the cellular pathways of RNA interference (RNAi)
[10]. The cellular circuits by which small ncRNAs can control ge-
netic programming are highly versatile and expand beyond post-
transcriptional gene control. SiRNAs, miRNAs and their effector
proteins can also guide processes like transcriptional gene silenc-
ing (TGS) [11–14] or activation (RNA activation, RNAa) [15–17]
and even alternative splicing [18]. Many of these processes inter-
twine with nuclear epigenetic pathways that control DNA methyl-
ation status, histone modiﬁcation, and chromatin remodeling
[13,17,19].
While there is still a lot to learn about the versatility of path-
ways and the exact molecular mechanisms by which siRNAs and
miRNAs perform their regulatory functions, recent reports demon-
strate that other, long-known, small ncRNAs such as small nucleo-
lar RNAs (snoRNA) and transfer RNAs (tRNA) expand beyond their
canonical pathways and give rise to even smaller RNA species that
operate in ways different from their precursor.2. Types, general characteristics, biogenesis, and function of
small non-coding RNA (ncRNA)
Within the diverse group of ncRNAs, the term small non-coding
RNA is given to a rather diverse group of ncRNA products with a
length of less than 400 nucleotides (nt) (Table 1).
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MiRNAs are single stranded RNA molecules of 22 nt that func-
tion as guide molecules for proteins of the AGO clade of the Arg-
onaute (Ago) family during post-transcriptional gene regulation
by the miRNA-induced silencing complex (miRISC). MiRNAs guide
the miRISC by base-pairing of the short (7–8 nt) miRNA ‘‘seed’’ re-
gion with partially complementary target sites of messenger RNAs
(mRNA), most commonly located in the 30-untranslated region
(UTR) [20].
Most miRNA are transcribed by RNA polymerase II (RNA Pol II)
from either clustered miRNA genomic loci of several kilobases (kb),
or co-transcriptionally from introns of other genes, generating
hairpin-structured primary precursor transcription units (pri-miR-
NAs) [21] (Fig. 1). In the classical miRNA pathway, pri-miRNA are
cropped at the hairpin stem to 70 nt long precursor hairpins
(pre-miRNAs) by the nuclear RNase III-type protein Drosha [6] as-
sisted by the DiGeorge syndrome critical region gene 8 protein
(DGCR8) [22]. Pre-miRNAs that originate from introns (mirtrons)
are produced in Drosha/DGCR8 independent way by intron splicing
and debranching, or via a splicing-independent, Drosha-dependent
manner (simtrons) [23]. After nuclear processing, pre-miRNAs are
exported to the cytoplasm by the nuclear transport receptor Expor-
tin 5 (EXP5, XPO5) [24] and cleaved close to the terminal loop by
the RNase III-type nuclease Dicer [25], releasing a 22 nt long dou-
ble stranded RNA duplex. One of the miRNA strands (referred to as
a guide or major strand (miRNA), is loaded onto an AGO protein to
generate the miRISC complex, while the other strand (passenger or
minor strand, miRNA) is degraded [21]. MiRNA strand selection
and loading are determined by the relative thermodynamic
strand-end stabilities of the miRNA duplex. The designated guide
strand is usually characterized by relatively lower stability at its
50-end caused by weaker base pairing (e.g. GU vs. GC pair or a mis-
match) [26,27]. In some cases, passenger strands can also be loaded
into RISC to function as miRNAs [28]. In mammals, AGO2, the only
one of the four AGO proteins with preserved RNaseH-like endonu-Table 1
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a HUGO Gene Nomenclature Committee (HGNC) (http://www.genenames.org/search)clease activity, can support Dicer processing by cleaving the 30-arm
of some pre-miRNAs [29]. The catalytically active AGO2 can also
process the unusually short pre-miR-451 hairpin into mature miR-
NA independently of Dicer. In this case, AGO2 performs the endo-
nucleolytic slicing of the 30-arm of the 17 nt long pre-miRNA stem.
This is followed by uridylation and exonucleolytic trimming of the
30-end by unknown nuclease to ﬁnally produce the mature miR-
451 [30–32].
Several lines of evidence over the last years revealed that miR-
NAs do not operate exclusively in the cytoplasm. Mature miRNAs
are also detected in the nucleus where they function in the pro-
cesses of transcriptional gene regulation similarly to synthetic dou-
ble stranded RNAs (reviewed in [16,17]). A prerequisite for these
processes is the import of activated miRNA/protein complexes to
the nucleus. It has been suggested that Exportin 1 (XPO1, CRM1)
and Importin 8 (IPO8) are involved in the nuclear-cytoplasmic
shuttling of cytoplasmically processed miRNAs complexed with
AGO proteins [33,34]. In the nucleus, miRNAs can serve as TGS trig-
gers by directing the association of AGO proteins with transcrip-
tional repressors from the Polycomb Group, leading to the
formation of silent-state heterochromatin at the promoter regions
of target genes. MiRNA-directed TGS was described for the ﬁrst
time for miR-320 and the DNA-directed RNA polymerase III poly-
peptide D gene (POLR3D) [35]. Similar mechanisms were demon-
strated also for miR-10a in human breast cancer cells [36], and
for miR-223 in hematopoietic progenitor cells during cell fate deci-
sion (reviewed in [13]). Recently, a cellular senescence model
based on miRNA-directed TGS was also proposed. In this model,
let-7 in complex with AGO2 recognizes promoter-associated RNAs
and cooperates with E2F/RB1 to induce or stabilize the repressed
chromatin state of target genes via the recruitment of histone
modifying enzymes [37].
Besides TGS, miRNAs are also involved in the process of RNAa,
where they function as endogenous signals for transcriptional acti-
vation. miRNA-directed RNAa was reported for miR-373 that acti-
vates E-Cadherin (CDH1) in prostate cancer cells by associatingn
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Fig. 1. Cross-talk between the pathways of biogenesis and function of miRNAs, snoRNAs, tRNAs, sdRNAs and tRFs. MiRNAs are encoded in clustered genomic loci or in the
introns of other genes and are transcribed by RNA polymerase II (RNA Pol II). Pri-miRNA transcripts are processed to individual pre-miRNAs in the nucleus by Drosha.
SnoRNAs and intron-encoded miRNAs are produced after splicing, debranching, and exonucleolytic trimming. Pre-miRNAs are exported to the cytoplasm by Exportin 5
(XPO5) and further processed by Dicer to mature miRNAs that enter the RNA-induced silencing complex (RISC). Cytoplasmically matured miRNAs in complex with proteins
from the Ago family (AGO) may be imported back in the nucleus possibly by Importin 8 (IPO8) to participate in the processes of transcriptional gene silencing (TGS) or RNA
activation (RNAa). SnoRNAs assemble with snoRNP-core proteins (not shown) and enter the nucleolus where they participate in the chemical modiﬁcation of ribosomal RNA
(rRNA) and other RNA species. SnoRNAs may be exported to the cytoplasm by unknown transporter proteins, where they are cleaved possibly by Dicer to short 22 nt long
sdRNAs and are loaded into RISC. Alternatively, snoRNAs may also be cleaved by unknown nucleases in the nucleus or nucleolus, to sdRNAs with a different size. Longer
sdRNAs of 27 nt do not exit the nucleus, but instead participate in the regulation of alternative splicing. tRNAs are transcribed from individual tRNA genes by RNA
polymerase III (RNA Pol III). Pre-tRNA transcripts are processed by the endonucleases RNase P and RNase Z to remove 50- and 30-trailer sequences, and after chemical
modiﬁcation, CCA addition, and aminoacylation, are exported to the cytoplasm by Exportin-t (XPOT) to participate in protein synthesis. 30U tRFs are produced by RNase Z after
trimming of the 30-trailer sequence. Stress factors may induce cleavage in the anticodon loop of mature tRNAs to tRNA halves performed by the endonuclease Angiogenin.
Shorter 50tRFs and 30CCA tRFs may be produced from 50- and 30-ends of mature tRNAs by Dicer and associate with AGO proteins to participate in various processes of
transcriptional and post-transcriptional regulation.
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1186, and -466d-3p that interact with the promoter of the mouse
Cyclin B1 gene to enhance cell proliferation [39]. The exact molec-
ular mechanisms of activating miRNAs are yet to be elucidated but
the involvement of components from the RNAi machinery and epi-
genetic events have been proposed [14,15,17,39].
Whether the involvement of miRNAs in transcriptional gene
regulation is a common process or is adopted from other (possibly
unknown) cellular mechanisms is to be investigated. However, the
examples mentioned above illustrate a broader functional ﬂexibil-
ity of small ncRNA and RNAi pathways in control of gene expres-
sion than previously thought.
2.2. snoRNA
Small nucleolar RNAs (snoRNA) are well-conserved, abundant,
short non-coding RNA molecules, 60–300 nucleotides (nt) in
length, which localize to a speciﬁc compartment of the cell nucleus
– the nucleolus. The majority of snoRNAs in vertebrates are en-
coded in the introns of protein coding or non-coding genes and
are transcribed simultaneously by RNA Pol II [40] (Fig. 1). Most
snoRNA host genes encode for proteins or transcripts essential
for ribosome biogenesis or function and often belong to the 50-ter-
minal oligopyrimidine (TOP) family that undergo growth-depen-
dent translational regulation. The generation of most intronic
snoRNAs involves splicing and debranching followed by a subse-
quent exonucleolytic trimming by the 50- to 30-exoribonuclease
XRN2 and the exosome [41,42]. A second, splicing-independent
pathway that generates intronic snoRNAs requires the endonucleo-
lytic cleavage of the pre-mRNA host transcript by the RNase III-like
enzyme Rnt1p in yeast [43]. Among higher eukaryotes this func-
tion is probably performed by homologues of the novel XendoU,
endoribonuclease superfamily [44]. Interestingly, the human
ortholog, ENDOU (human placental protein 11, PP11), is a tumor
marker, expressed in different forms of cancer [45].
SnoRNAs associate with small nucleolar ribonucleoprotein par-
ticles (snoRNP) and serve as guide molecules for the snoRNPs in
the post-transcriptional modiﬁcation of ribosomal RNA (rRNA)
and small nuclear RNA (snRNA). According to the presence of con-
served sequence motifs snoRNAs are sub-categorized into H/ACA-
box (SNORA) that guide pseudouridylation, and C/D-box (SNORD)
that guide 20O-ribose methylation of targeted RNA. The two types
of snoRNAs associate with distinct sets of proteins, necessary for
the proper formation and enzymatic function of the snoRNP.
SNORAs adopt a conserved double hairpin structure, where the
two irregular stems are linked by a hinge region containing the
conserved sequence motif 50-ANANNA-30 (H-box), and are followed
by a small tail containing the 50-ACA-30 motif (ACA-box). The hair-
pin stems contain short antisense elements complementary to the
target RNA positioned within an internal loop called the pseudou-
ridylation pocket [46]. The core H/ACA RNP includes the pseudou-
ridine synthase dyskerin (Cbf5p in yeast), and the proteins Nop10,
Nhp2, and Gar1 [47,48].
Interestingly, hTR, the RNA component of mammalian telome-
rase resembles SNORA RNA and its association with the core
H/ACA proteins is essential for the processing, stability, and traf-
ﬁcking of telomerase RNA in vivo [49,50].
SNORDs are characterized by the conserved structural motifs
50-RUGAUGA-30 (C-box) and 50-CUGA-30 (D-box). The C-box and
D-box form an unusual kink-turn (K-turn) structure, which is
essential for the folding, assembly, function, and nucleolar localiza-
tion of the snoRNP. A second internal C0/D0-box pair forms a K-loop
and is often degenerated in eukaryotes [51]. Substrate recognition
is achieved via the formation of a short (11–12 bp) double stranded
RNA helix between the targeted RNA and a short complementary
sequence stretch in the SNORD (antisense box) with the nucleotidetargeted for modiﬁcation positioned exactly 5 nt upstream of the D
or D0 box [46,52]. The formation of an active SNORD-RNP in
eukaryotes requires the association of Nop58/56 proteins with
the K-turn motif, which serves as a matrix for the binding and
proper positioning of the methyltransferase ﬁbrillarin [46].
A combination type of snoRNAs that comprises features of both
SNORAs and SNORDs localizes speciﬁcally to the Cajal bodies, small
sub-organelles in the nuclei of proliferative or metabolically active
cells involved in the biogenesis of small nuclear RNPs. Cajal-body-
speciﬁc RNAs (SCARNAs) contain a speciﬁc element, termed the Ca-
jal body box (CAB box) that is necessary for their retention within
the Cajal bodies [46]. SCARNAs can guide both the methylation and
pseudouridylation of the RNA Pol II transcribed spliceosomal RNAs.
To date, over 400 different snoRNA species have been identiﬁed
in the human genome [53]. However, target sites have been iden-
tiﬁed or predicted for only half of them. The remaining and
increasing number of snoRNAs that lack complementarity to other
RNA molecules, and therefore, have no known function, is referred
to as ‘‘orphan’’ snoRNAs [54].2.3. tRNA
tRNAs function as carriers that transport amino acids to the
growing polypeptide chain during the translation of mRNA. Mature
tRNAs are about 73 nt long and contain an amino acid attached to
their 30-ends. The secondary fold of a tRNA resembles a cloverleaf,
with three internal stem loops (D loop, T loop, and anticodon loop)
that interact with each other via conserved nucleotides to give a
compact L-shaped tertiary structure.
Up to 506 genes encoding a set of 49 different tRNAs are found
in the human genome [55]. tRNA genes are transcribed by RNA
polymerase III (RNA Pol III) (Fig. 1). Pre-tRNA transcripts have
the typical cloverleaf structure with additional 50-leader and 30-
trailer sequences of various lengths. The 50-leader sequence is re-
moved by the endoribonuclease P (RNase P), which has to recog-
nize the tRNA fold in order to perform the cleavage [56].
Endonucleolytic removal of the 30-trailer sequence is performed
by the endonuclease Z (RNase Z, ELAC2) [57]. After removal of
the 30-trailer, the terminal trinucleotide 50-CCA-30, obligatory for
the aminoacylation of tRNAs, is added at the 30-acceptor stem by
the CCA-adding tRNA nucleotidyl transferase, TRNT1 [58,59].
Some pre-tRNAs contain intronic sequences (14–60 nt in
length) positioned 30 to the anticodon that are removed by the evo-
lutionarily conserved tRNA splicing endonuclease [60] and the
tRNA splicing ligase complex [61]. During the process of matura-
tion, tRNAs also acquire many site-speciﬁc post-transcriptional
modiﬁcations that can inﬂuence the tRNA shape, structure, stabil-
ity, and function [62,63]. Finally, tRNAs are aminoacylated by
twenty different highly conserved aminoacyl-tRNA synthetases
(aaRSs), one for each canonical amino acid, and exported from
the nucleus by the nuclear transport receptor Exportin-t (XPOT,
XPO3) to participate in translation.
Although incredibly stable, tRNAs are subject to turnover and
degradation. Two quality control pathways monitor integrity of
tRNA during and after biogenesis. Nuclear surveillance of hypo-
modiﬁed pre-tRNAs and degradation from the 30-end of 30-unpro-
cessed pre-tRNAs is performed by the TRAMP complex and the
nuclear exosome. Mature tRNAs turnover is controlled by the Ra-
pid tRNA Decay (RTD) pathway from the 50-end (reviewed in
[64,65]).3. snoRNA-derived RNAs and tRNA-derived fragments
For a long time, snoRNAs and tRNAs have been considered as
cellular housekeeping molecules that maintain proper ribosomal
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years several independent NGS studies have demonstrated the
existence of small RNA species originating from snoRNAs and
tRNAs [66–73]. These small RNA molecules are often referred to
as snoRNA-derived RNAs (sdRNAs) [68] and tRNA-derived frag-
ments (tRFs) [69].
In experiments originally designed to proﬁle miRNAs, reads de-
rived from snoRNAs and tRNAs constitute only a minor fraction of
the total library (1.5–10% depending on the NGS platform and the
size-range of the original RNA fraction used for sequencing). There-
fore, sdRNAs and tRFs are often ignored from further analysis as
sequencing artifacts or degradation products of the much longer
mature snoRNAs and tRNAs. However, targeted and comparative
analysis of these small RNA populations and reanalysis of existing
sequencing data demonstrated that sdRNAs and tRFs are evolu-
tionary conserved across distantly related species and ubiquitous
in eukaryotes [66,68,74–78].
Most importantly, independent evidence from deep sequencing
studies, genetic screens, transcriptional, and molecular analyses
indicates that alterations in the expression of these small RNAs,
their precursors, or their genomic loci are associated with genetic
disorders [79–81] and malignancies such as prostate [69,82,83], li-
ver [66], lung [84,85] or breast cancer [86–88], B-cell lymphoma
[89], and acute leukemia [90,91], as well as with cancer related
processes like aging [77], oxidative stress [92–95], and embryonic
development [96,97].
4. sdRNAs - functional evidence, evolutionary characteristics,
and proposed mechanisms of action
4.1. sdRNAs can function as miRNAs
The ﬁrst functional evidence demonstrating miRNA-like activity
for an sdRNA was obtained by RNA deep sequencing of immuno-
precipitated AGO1 and AGO2 complexes from Human Embryonic
Kidney 293 cells (HEK293). This sdRNA, originating from SCAR-
NA15 (ACA45), was produced in a Drosha/DGCR8-independent, Di-
cer-dependent manner. Luciferase reporter assays targeting its
predicted target cyclin-dependent kinase 11B (CDK11B), demon-
strated its miRNA-like activity [67]. The same authors identiﬁed
seven additional sdRNAs with miRNA-like processing features orig-
inating from two SCARNAs and ﬁve SNORAs in follow-up experi-
ments with newly designed AGO1-4 libraries. Parallel NGS
studies of the small transcriptome in mice revealed the presence
of SNORA-originating miRNAs in embryonic stem cells and demon-
strated that sdRNAs exhibit tissue speciﬁc expression [98,99].
At the same time, SNORD-originating miRNAs were described in
the protozoan Giardia lamblia, a unicellular parasite whose genome
does not encode Drosha and XPO5. These miRNA-like sdRNAs are
produced in a Drosha/DGCR8-independent, Dicer-dependent man-
ner [100,101]. The same pathway was described one year later in
cells infected with the Epstein-Bar virus (EBV). In this system,
EBV expresses a miRNA-like precursor endogenously encoded by
a viral SNORD (v-snoRNA1) to suppress the viral DNA polymerase
upon induction of the lytic cycle [102]. Several small RNA deep
sequencing studies in the last few years extended the catalogue
of sdRNAs further by detecting sdRNA species originating from C/
D box snoRNAs in different normal and cancerous human cells
and tissues [73,78,83,103]. Efﬁcient gene silencing in vitro by
SNORD-sdRNA was also reported, indicating the existence of cyto-
plasmic processing and recruitment to the RNA silencing machin-
ery for this type of sdRNAs [73].
The obvious similarities in the generation of sdRNA and mir-
trons, as well as the accumulating functional evidence of silencing
capacities for sdRNAs, led to investigation of the possible evolu-
tionary relationship between miRNAs and snoRNAs. It was shownthat the genomic loci of some bona ﬁdemiRNAs overlap with those
of snoRNA, and that many of these miRNAs resemble the structures
of known snoRNAs. Furthermore, such miRNAs still contain func-
tional snoRNA elements and can bind protein components of
snoRNP complexes. Together, this led to the proposition that miR-
NAs and snoRNAs share ancestral origins and that miRNAs may
have evolved from ancient snoRNAs via retrotransposition ([103–
105] and reviewed in [106]).
4.2. SNORD-sdRNAs as regulators of alternative splicing
The above described repression of complementary reporter-tar-
gets by sdRNA, their association with Dicer and AGO complexes,
and their apparently common evolutionary origin support microR-
NA-like processing and activity for sdRNAs. However, while SNO-
RA-sdRNAs have the typical size of Dicer products and are 22 nt
long, most SNORD-sdRNAs detected in deep sequencing data dis-
play a bimodal size distribution at 18 and 27 nt [68,73,83], sug-
gesting the involvement of other nuclease(s) in SNORD-sdRNAs
generation. A microRNA-biogenesis protein that could be involved
also in the biogenesis of SNORD-sdRNAs is AGO2. AGO2 can per-
form the Dicer-independent cleavage of pre-miRNA-451 (de-
scribed above). Nonetheless, the mature miRNA-451 is
predominantly 30-uridilated, while most of the SNORD-sdRNAs
are not, pointing out to a still unknown mechanism that generates
longer SNORD-sdRNAs.
Interestingly, the highly abundant ‘‘orphan’’ SNORD115 (H/
MBII-52) and SNORD116 (N/MBII-85) produce even larger sdRNAs
of 34–73 nt in length originally termed psnoRNAs [79,107]. Both
snoRNAs are encoded in long gene clusters at the human
15q11q13 locus. SNORD116 has been implicated in the imprinted
Prader-Willi Syndrome [108], while SNORD115 was proposed to
regulate the alternative splicing of serotonin receptor 2C (HTR2C)
mRNA [109]. Surprisingly, follow-up research on SNORD115 dem-
onstrated that not the full-length SNORD115 but sdRNAs derived
from this ‘‘orphan’’ snoRNA recruit spliceosomal factors and regu-
late the alternative splicing of HTR2C [79]. Recently, the function of
SNORD115-originating sdRNAs in alternative splicing was chal-
lenged by another study which conﬁrmed the processing of
SNORD115 and SNORD116 to smaller RNAs but proposed a bona
ﬁde snoRNA function for these molecules [110]. Nonetheless, a
more detailed analysis of the conservation of human SNORDs pro-
cessing across multiple cell types demonstrated that a region of
SNORD88C (HBII-180C) can inﬂuence the alternative splicing of
the ﬁbroblast growth factor receptor 3 pre-mRNA (FGFR3), sup-
porting the role of some sdRNAs in regulation of splicing [78]. Fur-
thermore, over hundred alternative splicing target sites for
SNORD115–116 and ﬁve other ‘‘orphan’’ SNORDs from the
15q11q13 locus were computationally predicted to have signiﬁ-
cant association with alternatively spliced genes [111].
So far, no biogenesis mechanisms have been proposed for sdR-
NAs originating from SNORD88C, SNORD115, or SNORD116 and
their involvement in alternative splicing has to be investigated fur-
ther. Nevertheless, regulation of exon-skipping or exon-inclusion is
an attractive hypothesis for the function of sdRNAs originating
from ‘‘orphan’’ SNORDs and it is supported by data obtained from
experimental use of synthetic short RNAs mimicking snoRNA (re-
viewed in [112]). Furthermore, regulation of alternative splicing
through siRNA-mediated TGS was also reported, demonstrating
the existence of an ncRNA controlled point of intersect between
the processes of gene transcription and splicing [18].
4.3. snoRNAs and sdRNAs as tumor suppressors and oncogenes
One of the ﬁrst implications of snoRNAs in carcinogenesis came
from a study in human B-cell lymphoma which identiﬁed the
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netic locus of intronically encoded SNORD50 (U50) [89]. Eight
years later, a 2 bp homozygous deletion in the same snoRNA was
found in 30 prostate cancer cell lines/xenografts and nine out of
89 localized prostate cancers but not in the 104 normal controls.
Ectopic expression of SNORD50 signiﬁcantly reduced colony for-
mation in prostate cancer cells. Further analysis of 1371 prostate
cancer cases and matched controls showed that, the homozygosity
of this deletion was signiﬁcantly associated with clinically signiﬁ-
cant prostate cancer and allowed the authors to propose U50 as a
candidate tumor-suppressor gene in prostate cancer [82] and one
year later in breast cancer [86].
Recently, four snoRNAs (SNORD44, SNORD43, SNORD48 and
RNU6B) often used as normalization controls in real-time PCR
experiments were proﬁled in 219 breast cancers and 46 head
and neck squamous cell carcinomas [88]. Interestingly, low snoR-
NA expression correlated with markers of aggressive pathology,
while decreased levels of SNORD44 (RNU44) were also associated
with a poor prognosis. The full length SNORD44 is encoded in
one of the introns of the protein non-coding growth arrest speciﬁc
transcript (GAS5) shown to be down-regulated in breast tumors
compared to normal adjacent controls [113]. Interestingly, sdRNAs
derived from SNORD44, SNORD78 and other snoRNAs encoded in
GAS5 are up-regulated in prostate cancer [83], which suggests that
separate mechanisms may control the post-transcriptional levels
of snoRNA products derived from the same precursor transcript.
Similarly, divergent expression between a snoRNA host gene tran-
script and the snoRNAs encoded in its introns has been described
for the conserved mouse ortholog of human ZFAS1 gene known
to be down-regulated in breast cancer [87].
Another example of a snoRNA that is positively associated with
carcinogenesis and thought to be a putative oncogene is SNO-
RA42. SNORA42 is located at 1q22, a genomic region frequently
subjected to ampliﬁcation in lung carcinomas [114]. This snoRNA
is also commonly overexpressed in lung tumors [93]. For SNO-
RA42 it has been shown that a knockdown in non-small-cell-lung
carcinoma (NSCLC) cells inhibits in vitro and in vivo tumorigenic-
ity. Enforced SNORA42 expression in bronchial epithelium in-
creases cell growth and colony formation. It was also
demonstrated that SNORA42 expression in lung tumor tissue
specimens is inversely correlated with survival of NSCLC patients
[85].
A speciﬁc snoRNA down-regulation pattern allowing the differ-
entiation between tumor and control samples was also recently
observed in acute leukemia [90]. The same study reported snoRNA
expression signature speciﬁc for a subset of patients with acute
promyelocytic leukemia. This signature corresponds to transcrip-
tional activation of restricted chromosomal regions encoding the
‘‘orphan’’ intronic SNORD112–114 cluster. In vitro experiments
demonstrated that transcription of these snoRNAs was lost under
retinoic acid-mediated differentiation and induced by enforced
expression of the PML–RAR alpha fusion protein in negative leuke-
mic cell lines. These results led to the hypothesis that snoRNAs
might be speciﬁcally regulated in a background of chromosome
instability and thus may have an important role in oncogenesis,
similarly to miRNAs.
Finally, an indication that snoRNAs are also targeted by epige-
netic inactivation in human cancer came from the observed
hypermethylation and inactivation of snoRNA host gene-associ-
ated 50-CpG islands. This led to transcriptional silencing of the
snoRNAs SNORD123, SNORA70C and SNORA59B in cancer cells
and primary malignancies, particularly in leukemia [91].
At present, it remains to be discovered whether the altered
expression of sdRNAs and/or their snoRNA precursors in cancer is
the result of a speciﬁc process or of more general defects in cellular
metabolism caused by malignant transformation and cancerprogression. The exact molecular mechanisms by which snoRNAs
and sdRNAs may provoke cell survival and proliferation and inhibit
cell death in vivo remain unknown and should be the subject of fur-
ther investigations.5. tRNA fragments – types, functional evidence, and proposed
action mechanisms
Already in the early 1970s, the expression of a fragment derived
from tRNAleu, was observed in Escherichia coli shortly after bacte-
riophage T4 infection [115]. Almost 30 years later, a tRF was iso-
lated from human urinary bladder carcinoma and for the ﬁrst
time also functionally studied [116]. By now, the generation of
NGS data led to the identiﬁcation of small tRNA fragments of dif-
ferent size and origin on a genome wide scale and is starting to ad-
dress the questions surrounding their biogenesis and function
[66,69,70,72,75,117,118].
5.1. Types of tRNA fragments
Since their discovery, the terminology regarding small ncRNAs
derived from tRNAs has been highly inconsistent. Names such as
tRNA halves [74,94], tRNA-derived halves [119], tRNA-derived
RNA fragments (tRFs) [69] stress-induced small RNAs (tiRNAs)
[95,120], tRNA-derived small RNAs (tsRNAs) [117] or urinary blad-
der carcinoma RNAs (ubcRNAs) [116] are used by various research
groups and refer to similar entities. Recently, a nomenclature
based on tRNA fragment size and the part of the tRNA molecule
from which fragments are derived was proposed [121]. According
to this nomenclature, tRNA fragments can be separated in two ma-
jor classes: tRNA halves and small tRNA fragments (tRFs). tRNA
halves have a size of 30–35 nt and are produced by a cleavage in
or near the anticodon loop in response to hypoxia, oxidative stress,
or apoptotic inducers [74,93,94]. Interestingly, Angiogenin, the
endonuclease responsible for this cleavage in mammals [94,95] is
a potent vascularization agent in normal and malignant cells and
a potential oncogene.
Small tRFs of approximately 20 nt in length are derived from
either the 50- or 30-end of mature tRNAs (50tRF and 30CCA tRFs).
tRFs are also produced from 30-pre-tRNA trailers (30U tRFs) during
processing of pre-tRNAs by RNase Z, a nuclease also known as the
prostate cancer susceptibility gene ELAC2 [69] (Fig. 1). The mech-
anisms by which 50- and 30CAA tRFs are generated in the cell are
not yet completely understood but it has been proposed that Dicer
may be involved in tRFs production [70].
5.2. Are tRNA fragments degradation products of tRNA or novel
biological entities?
The abundance of tRNAs, their ubiquitous expression and their
central role in cellular metabolism impose the question whether
tRNA fragments often found in sequencing experiments are func-
tional entities or ‘‘just’’ products of tRNA turnover and cellular
stress response.
Several lines of evidence demonstrate that tRNA fragments are
produced in a controlled fashion suggesting that these small RNA
molecules are novel biological entities. For example, levels of ma-
ture tRNA do not change signiﬁcantly during stress induced tRNA
cleavage and tRNA halves production [74,93,95]. Furthermore,
the process seems to be controlled by RNA methylation [122],
and it is induced only by speciﬁc instead of all stress stimuli
[123]. Next, cleavage often occurs at speciﬁc positions in tRNA sug-
gesting that fragments are derived from fully mature tRNAs, after
intron excision and 50-CCA-30 addition (reviewed by [121]). Finally,
a recent detailed analysis of human healthy, cancerous, or
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increase in absolute tRNA gene levels in cancerous compared to
healthy cells, the relative composition of full length tRNAs remains
almost identical and it is not associated with tRF abundance [124].
This study conﬁrms the original ﬁndings by Kawaji et al. [66] that
tRF frequencies have no correlation with tRNA gene copy number
or codon usage distribution. It also rejects the hypothesis that
tRF abundance reﬂects tRNA gene expression and provides addi-
tional evidence that tRFs are independent entities and not a prod-
uct of tRNA turnover and degradation.
5.3. Biological role and action mechanisms of tRNA-derived small RNAs
Although, the exact roles of tRNA halves and tRFs are yet to be
elucidated, accumulating evidence suggests that tRNA-derived
small RNAs participate in two main types of biological processes.
5.3.1. tRNA-derived fragments as signal molecules in stress induced
response
By now, several investigations have shown that tRNA halves are
up-regulated by stress conditions and particularly under starva-
tion-induced and oxidative stress [93,95,123]. tRNA halves can
promote the assembly of stress granules [120], a type of cytoplas-
mic RNPs, that play an important role during stress-induced trans-
lational inhibition and translational induction of cell-repair and
cell-survival proteins [125]. In this context, promotion of stress
granule assembly by tRNA-derived fragments may play an impor-
tant signaling role for hypoxia and starvation-induced stress in tu-
mor cells [126]. Interestingly, there is also evidence that tRNAs can
inhibit apoptosis via association with cytosolic cytochrome-C, pre-
venting its interaction with Apaf-1 and blocking subsequent cas-
pase-9 activation. At the same time, treatment with tRNA-
speciﬁc RNase enhances caspase-9 activation and apoptosis
[127]. On the contrary, it has been shown that tRFs are up-regu-
lated in prostate cancer [83]. Furthermore, in prostate cancer cell
lines, 30U tRFs expression positively correlates with the cellular
proliferation rate and siRNA mediated 30U tRF knockdown results
in impaired cell proliferation [69].
Taken together, tRFs seem to participate in cellular stress re-
sponse and to inﬂuence cell proliferation. Stress conditions such
as nutritional starvation or oxidative stress, often precede apopto-
sis but are also common in the tumor environment. In most of
these conditions the expression of tRNA-derived fragments raises
proportionally [93,123]. It is possible that in normal cells tRNA-de-
rived fragments function as intrinsic apoptotic signals or cause
apoptosis indirectly, by e.g., inhibition of protein translation. It also
can be assumed that the pathways of stress-related tRNA cleavage
interact or intercept with major cancer pathways that lead to
apoptosis escape and induce proliferation of malignant cells. Fur-
ther research is needed to elucidate the exact pathways of genera-
tion and function of stress-induced tRNA fragments and their role
in cancer biology.
5.3.2. tRNA-derived fragments as regulators of gene expression
One of the ﬁrst reports suggesting involvement of tRNA-derived
fragments in gene regulation and silencing, addressed the charac-
terization of small RNAs in human immunodeﬁciency virus (HIV)
infected cells [128]. In this study, Yeung et al., reported the identi-
ﬁcation of a highly abundant, 18 nt long, small RNA, originating
from the double-stranded RNA hybrid formed by the HIV primer-
binding site and the 30-end of the human cellular tRNAlys. tRNAlys
is one of the three tRNAs (tRNAlys, tRNApro, or tRNAtrp) used by viral
reverse transcriptases as primers for the initiation of reverse tran-
scription and DNA synthesis [129,130]. The association of this
tRNAlys-derived 30tRF with Dicer and AGO2, and its silencing activ-
ity in luciferase reporter assays, led to a proposed function in thecellular RNA interference (RNAi) machinery for targeting HIV and
viral defense.
Interestingly, mammalian herpes viruses have adopted the
tRNA biogenesis pathway to generate fully functional viral miR-
NAs. In this system, short transcripts containing a 50 tRNA-like
molecule ﬂanked by a 30-pre-miRNA hairpin are produced by
RNA Pol III and subsequently cleaved by the cellular RNase Z to lib-
erate the pre-miRNA hairpins, which are further processed to ma-
ture viral miRNAs by Dicer [118,131,132]. Similar structures, also
giving rise to small RNAs, have been found in the mouse host gen-
ome, indicating a convergent usage of RNA Pol III transcripts for the
generation of small RNAs from both mammalian and viral genomes
[118]. In the human genome, a highly conserved tRNA-like struc-
ture (mascRNA) is processed from the 30-region of MALAT1, a long
non-coding RNA known to be deregulated in many human cancers.
MascRNA is processed by RNase P and RNase Z and is subjected to
CCA addition to generate the mature 61 nt mascRNA transcript,
which is subsequently exported to the cytoplasm [133]. Although
the function of mascRNA is still unknown, its existence in the hu-
man genome is probably not a solitary event. Recently, a tRNA-like
cloverleaf structure similar to tRNAgly was discovered in the intron
of the POP1 gene encoding one of the protein subunits of RNase P
that interact with the 50-end of tRNAs. For this POP1-ncRNA a func-
tion in auto-regulation of the POP1 transcripts was proposed, with
the RNase P complex binding and potentially cleaving the hybrid
[134].
The miRNA generation system adopted by murine herpes
viruses strikingly resembles the production of a 30U tRF (tRF-
1001, cand45) described in prostate cancer cell lines [69] and in
human hepatitis delta transformed embryonic kidney cells
[117]. However, in contrast to viruses, no silencing activity could
be demonstrated for this tRF in luciferase reporter assays, sug-
gesting that 30U tRFs operate in pathways other than miRNAs
[69,117]. Furthermore, predominant association of 30U tRFs was
observed with AGO3 and AGO4 [117] whose function at present
is largely unknown. The same study reported a similar association
with AGO proteins also for 30CCA tRFs, which however did dem-
onstrate modest silencing effect in reporter assays. Interestingly,
strikingly similar 30CCA tRFs from Tetrahymena associate with
the growth-essential PIWI protein Twi12 and may represent an
ancient pathway of gene regulation or heterochromatin formation
[135].
Similarly to 30tRNA-derived fragments, small 50tRFs do not seem
to associate strongly with AGO2 but instead preferentially associ-
ate with AGO1 [70,71]. Interestingly AGO1 has been implicated
in transcriptional gene silencing via heterochromatin formation
mediated by siRNAs and miRNAs targeting promoter regions in hu-
man cells [14,35,136]. This proposes a participation in the TGS
pathways (discussed in Section 2.1) also for tRNA-derived
fragments.
Last year, Rudinger-Thirion et al. demonstrated that the poorly
aminoacylated human tRNAasp isodecoder could adopt an alterna-
tive hairpin secondary structure. In this isoform, tRNAasp binds to
an embedded Alu element in the 30UTR of its aspartyl-tRNA syn-
thase mRNA and stabilizes the mRNA for efﬁcient translation
[137]. Interestingly, tRNAasp binds the Alu element via extensive
base pairing from positions 21 trough 55, leaving the 20 nt long
50-terminal portion of the tRNA (that in size and position resembles
a 50tRF) exposed and accessible for nuclease cleavage. The results
of this study demonstrate not only a possible function for the many
tRNA isodecoders and pseudogenes, but also hint to an unantici-
pated way of tRF generation.
Finally, a recent deep sequencing study and a computational
comparison of human cancer cells and mouse embryonic cells by
Li et al. [72] demonstrated the presence of 16–18 nt long 30CCA
tRFs that do not undergo Dicer processing but are endogenously
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target RNAs in vitro. Interestingly, these small tRFs are highly com-
plementary to endogenous retroviral primer binding sites in the
human genome. Therefore a role in regulating the unwarranted
expression of endogenous viruses through the RNA interference
pathway was proposed for these tRFs.
Taken together, although tRNA-derived fragments seem to be
highly abundant, currently, their actual functions remain un-
known. Nevertheless, a growing body of evidence suggests that
tRFs can act as signaling molecules under stress conditions and
in gene regulation by alternative mechanisms possibly evolved
from ancient regulatory pathways. Additional research addressing
the molecular partners of these tiny RNAs and development of
computational tools for the prediction of their targets is warranted
and necessary in order to elucidate the exact pathways in which
they operate.6. Future perspectives
At present, the interest in small RNAs other than miRNAs is rap-
idly growing. Their involvement in cancer and other human dis-
eases has provided fresh perspectives for the exploration and
development of new biomarkers and novel therapeutic strategies
for the detection, monitoring, and treatment of human disease.
6.1. Biomarker potential
The high stability and abundance of miRNAs in body ﬂuids and
their power to discriminate cancer patients from healthy controls
[138], opened the prospect for development of minimally invasive,
ncRNA-based biomarker tests for the detection and monitoring of
solid tumors. Although current research is primarily focused on
miRNAs as candidate ﬂuid-based biomarkers, the involvement of
sdRNAs, tRFs, and their precursor molecules in pathological pro-
cesses and the demonstrated differential expression in solid tu-
mors [83–85,88] and hematological malignancies [89,90] suggest
yet unexploited clinical potential also for these ncRNAs. Speciﬁc
cancer-related snoRNA signatures in blood plasma were recently
described for non-small-cell lung cancer [84]. Already in the late
1970s, elevated levels of tRNA breakdown products were found
in the urine of humans and mice with different malignancies
[139] and earlier this year, fragments of the spliceosomal small nu-
clear RNA, RNU2 were found in human serum and plasma from
pancreatic and colorectal carcinoma. qRT-PCR based assays cor-
rectly identiﬁed both tumor types with a very high sensitivity
and speciﬁcity [140], demonstrating that also small RNA fragments
may be used as ﬂuid-based biomarkers in future prospective
screening studies.
6.2. Therapeutic potential
At present, attention for RNA-based therapeutics that mimic or
regulate miRNA activity is growing. Strategies, that utilize modi-
ﬁed antisense oligonucleotides like locked nucleic acid (LNA) oligo-
nucleotides to inhibit miRNA function, or miRNA mimics to restore
it, are routinely used in miRNA research. Therapeutic agents based
on tiny LNAs for the treatment of hepatitis C [141], lymphoma
[142] and metastatic solid tumors [143] have entered clinical trials.
Similar strategies can be easily adopted in the future for cancer-
associated miRNA-like sdRNAs or tRFs to inhibit the function of
oncogenic sdRNAs/tRFs or to restore the cellular levels of tumor-
suppressive ones.
Elucidation of the molecular mechanisms by which sdRNAs and
tRFs function in regulation of gene expression can generate novel
molecular tools for the modulation of functional restoration ofother oncogenes or tumor-suppressor genes in the malignant cell.
For example, snoRNA-based vector systems for the (simultaneous)
targeted knockdown of one or more RNA transcripts already exist.
They have been proven effective in the speciﬁc knockdown or
replacement of the targeted endogenous proteins and could be uti-
lized in basic gene expression research and target validation, but
also for gene therapy [144]. Furthermore, if at least some ‘‘orphan’’
sdRNAs are proven to regulate cancer associated alternative cis- or
trans-splicing events, synthetic sdRNA-like constructs can be
developed and used for the repair of transcripts that are subject
to misprocessed splicing in cancer. Such strategies based on splic-
ing modulation mediated by antisense oligonucleotides are cur-
rently used to restore cryptic splicing, to change levels of
alternatively spliced genes, or, in case of Duchenne muscular dys-
trophy for exon-skipping in order to restore a disrupted reading
frame [145].
A better understanding of the function of tRNAs in apoptosis,
and the involvement of tRFs in stress signaling, may help to devel-
op methods for the repair of malfunctioning signaling pathways
associated with cancer and can lead in the future to novel treat-
ment strategies in early stages of cancer.
In conclusion, the further development of NGS technologies,
computational algorithms for the prediction and analysis of ncRNA,
and the expanding data on the (aberrant) expression of known and
newly discovered small RNAs, will without doubt deepen our
knowledge of their function in the normal and malignant cell.
For now however, the mechanistic pathways in which sdRNAs
and tRFs are generated and function, remain to be elucidated,
while existing hypotheses are still to be scrutinized and function-
ally examined in vitro and in vivo, before we gain a comprehensive
view of the biology of small non-coding RNA.
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